– Novo Nordisk A/S and Valo Health, Inc. today announced they have entered into an expanded agreement to discover and develop novel treatments for obesity, type 2 diabetes, and cardiovascular disease based on Valo’s extensive human dataset and computation powered by artificial intelligence (AI).

–Novo Nordisk A/S和Valo Health，Inc.今天宣布，他们已达成一项扩大协议，根据Valo广泛的人类数据集和人工智能（AI）支持的计算，发现并开发针对肥胖、2型糖尿病和心血管疾病的新型治疗方法。

The companies originally partnered in September 2023 in an agreement that allowed for the development of up to 11 drug programmes, primarily focused on cardiovascular disease, through which Valo was eligible to receive up to 2.7 billion US dollars in milestone payments, plus R&D funding and potential royalty payments.

两家公司最初于 2023 年 9 月达成合作协议，允许开发多达 11 个药物项目，主要针对心血管疾病，通过该协议，Valo 有资格获得高达 27 亿美元的里程碑付款，外加研发资金和潜在的特许权使用费。

Under the terms of the expanded agreement, Valo is entitled to receive an upfront payment, equity investment, and a potential near-term milestone payment, totalling 190 million dollars, and is now eligible to receive milestone payments for up to 20 drug programmes, an addition of 9 new drug programmes, totalling approximately 4.6 billion dollars, plus R&D funding and potential royalty payments..

根据扩展协议的条款，Valo有权获得预付款，股权投资和潜在的近期里程碑付款，总额为1.9亿美元，现在有资格获得多达20个药物计划的里程碑付款，另外9个新药计划，总额约为46亿美元，加上研发资金和潜在的版税付款。。

The expanded collaboration will continue to leverage the capabilities of Valo’s Opal Computational Platform™, as well as key joint capabilities in human data and genetics with Novo Nordisk’s expertise in cardiometabolic diseases.

扩大的合作将继续利用Valo的Opal计算平台™的功能，以及人类数据和遗传学方面的关键联合能力，以及诺和诺德在心脏代谢疾病方面的专业知识。

“We are very pleased with the progress we have made together with Valo during the first year of our collaboration, and we are excited to expand the scope to put a stronger focus on obesity and type 2 diabetes in addition to cardiovascular disease,” said Marcus Schindler, executive vice president and chief scientific officer of Novo Nordisk.

诺和诺德执行副总裁兼首席科学官马库斯·辛德勒（Marcus Schindler）表示：“我们对在合作的第一年与瓦洛（Valo）合作取得的进展感到非常高兴，我们很高兴扩大合作范围，将重点放在肥胖和2型糖尿病以及心血管疾病上。”。

“We have already begun to realize the potential of combining the capabilities of Valo and Novo Nordisk to advance multiple AI-powered, human-centric programmes, and we believe this partnership will help Novo Nordisk fulfil our ambition to expand the number of new drug programmes we bring to the clinic.”.

“我们已经开始意识到结合Valo和Novo Nordisk的能力来推进多种人工智能支持的以人为中心的计划的潜力，我们相信这种合作关系将帮助Novo Nordisk实现我们的雄心壮志，扩大我们为诊所带来的新药计划的数量。”。

The collaboration has already led to the identification of several novel targets that may form the basis of differentiated cardiometabolic drug programmes, and the companies are actively working on multiple small molecule preclinical drug discovery programmes.

这项合作已经确定了几个新的靶点，这些靶点可能构成差异化心脏代谢药物计划的基础，这些公司正在积极研究多个小分子临床前药物发现计划。

“We are excited to build off our early progress with Novo Nordisk, a global leader in obesity and diabetes therapeutics, especially given the renaissance moment in the treatment of cardiometabolic diseases. This level of investment is a testament to our close partnership in deploying human-centric artificial intelligence to rapidly discover and develop novel cardiovascular and metabolic disease therapeutics,” said Brian Alexander, CEO of Valo Health and CEO-Partner, Flagship Pioneering.

Valo Health首席执行官兼旗舰先锋首席执行官合伙人布莱恩·亚历山大（Brian Alexander）表示：“我们很高兴与肥胖和糖尿病治疗领域的全球领导者诺和诺德（Novo Nordisk）取得早期进展，尤其是考虑到心脏代谢疾病治疗的复兴时刻。这一投资水平证明了我们在部署以人为中心的人工智能以快速发现和开发新型心血管和代谢疾病治疗方法方面的密切合作关系。”。

“The partnership fully leverages the Opal Computational Platform by seeking to identify novel therapeutic targets in large real-world patient datasets, validate those targets using human preclinical models, and develop therapeutics against those targets with human-centric AI small molecule design.”.

“该合作伙伴关系充分利用Opal计算平台，寻求在大型现实世界患者数据集中识别新的治疗靶点，使用人类临床前模型验证这些靶点，并通过以人为中心的AI小分子设计开发针对这些靶点的治疗剂。”。

The expanded collaboration allows for a deeper partnership between the two companies, with activities that span the entire drug discovery continuum. Novo Nordisk and Valo plan to continue working closely together to derive novel insights from human genetic and longitudinal patient data at the intersection of obesity, type 2 diabetes, and cardiovascular disease..

扩大的合作允许两家公司之间建立更深入的合作关系，其活动涵盖整个药物发现过程。诺和诺德和瓦洛计划继续密切合作，从肥胖、2型糖尿病和心血管疾病交叉点的人类遗传和纵向患者数据中获得新的见解。。

About Valo Health

关于Valo Health

Valo Health, Inc is leveraging artificial intelligence (AI) and advanced analytics to better learn from the patient experience to discover and develop better medicines at greater speed and scale. The company’s Opal Platform™ is a human-centric AI-driven drug development engine that uses AI to identify and validate novel drug targets using real world data and human models to rapidly discover and develop small molecule therapies against those targets with more predictable safety and efficacy.

Valo Health，Inc正在利用人工智能（AI）和高级分析技术，更好地从患者体验中学习，以更快的速度和规模发现和开发更好的药物。该公司的Opal Platform™是一个以人为中心的人工智能驱动的药物开发引擎，它使用人工智能来识别和验证新的药物靶标，使用真实世界的数据和人体模型来快速发现和开发针对这些靶标的小分子疗法，具有更可预测的安全性和有效性。

Founded by Flagship Pioneering and headquartered in Lexington, MA, Valo also has offices in New York, NY and Tel Aviv, Israel. To learn more, visit .

Valo由Flagship Expediantive创立，总部位于马萨诸塞州列克星敦，在纽约州和以色列特拉维夫也设有办事处。要了解更多信息，请访问。

About Novo Nordisk

诺和诺德

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease.

诺和诺德是一家领先的全球医疗保健公司，成立于1923年，总部位于丹麦。我们的宗旨是推动变革，战胜严重的慢性疾病，这是我们在糖尿病方面的传统。我们通过开创科学突破、扩大药品的使用范围以及努力预防和最终治愈疾病来实现这一目标。

Novo Nordisk employs about 72,000 people in 80 countries and markets its products in around 170 countries.

诺和诺德在80个国家拥有约72000名员工，产品销往约170个国家。